LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...
AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...
No evidence of human transmission, but virus found in increasing number of animals World Health Organization says H5N1's risk ...
AstraZeneca’s new U.S. spending also leaves in doubt the pharmaceutical company’s plans to invest in a vaccine site in ...
In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...
The company said it aims to expand its U.S. presence by the end of 2026. The new spending will be for a research-and-development center in Cambridge, Mass.; manufacturing plants in Maryland and Texas, ...
On the heels of releasing its latest financial statement, Vancouver-based biotechnology company Absci announced it has met its first milestone in its collaboration with pharmaceutical giant AstraZenec ...
The holidays are fast approaching along with cooler weather and various respiratory illnesses. Here's when to get your ...
The FDA has lifted its clinical hold on Novavax's combined COVID-19 and influenza vaccine trial, finding no link between the ...
GlobalData on MSN18h
FDA clears Novavax to resume trials of Covid-19 and flu combo vaccineNovavax has received the green light from the US Food and Drug Administration (FDA) to resume clinical trials for its ...
Reactogenicity is comparable for simultaneous and sequential administration of mRNA COVID-19 and influenza vaccines.
See your plan by selecting location, age, and other applicable factors Sign up to be alerted when there are vaccination updates in your state: The Plan Your Vaccine page will be updated as new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback